Background: In patients with bladder cancer (BCa) preoperative staging with 11C-choline positron emission tomography-computed tomography (PET/CT) could be used to derive prognostic information and hence stratify patients preoperatively with respect to disease management. Methods: From June 2004 to May 2007, 44 patients with localized BCa were staged with 11C-choline PET/CT before radical cystectomy. The results of imaging were correlated to overall survival (OS) and cumulative incidence of cancer-specific death (CSD). Results: There was no statistically significant difference in OS and CSD between the patient groups when stratified for organ-confined versus non-organ-confined disease or lymph node involvement defined by either 11C-choline PET/CT (OS: p = 0.262, hazard ratio [HR] = 1.60; p = 0.527, HR = 0.76; CSD: p = 0.144, HR = 2.25; p = 0.976, HR = 0.98) or CT (OS: p = 0.518, HR = 1.34; p = 0.228, HR = 1.67; CSD: p = 0.323, HR = 1.90; p = 0.136, HR = 2.38). The limitation of this study is the small number of included patients. Conclusion: In our prospective trial neither CT nor 11C-choline PET/CT were able to sufficiently predict OS or CSD in BCa patients treated with radical cystectomy albeit trends and moderately increased HRs could be demonstrated without significant differences between CT or 11C-choline PET/CT. However, these trends might prove statistically significant in bigger patient cohorts. Therefore initial transsectional imaging might be of clinical relevance in respect to prognosis and could play a role in the counseling of BCa patients.

Keywords:
Bladder cancer, Choline, Positron emission tomography- computed tomography, Cancer-specific death, Overall survival
1.
Stenzl A, Witjes JA, Compérat E, Cowan NC, De Santis M, Kuczyk M, Lebret T, Ribal MJ, Sherif A: Guidelines on bladder cancer muscle-invasive and metastatic. Edition presented at the 27th EAU Annual Congress, Paris, 2012. http://www.uroweb.org/gls/pdf/07_Bladder%20Cancer_LR%20II.pdf.
2.
Bosetti C, Bertuccio P, Chatenoud L, Negri E, La Vecchia C, Levi F: Trends in mortality from urologic cancers in Europe, 1970-2008. Eur Urol 2011;60:1-15.
3.
Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-866.
4.
Advanced Bladder Cancer Meta-analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003;361:1927-1934.
5.
Turker P, Bostrom PJ, Wroclawski ML, van Rhijn B, Kortekangas H, Kuk C, Mirtti T, Fleshner NE, Jewett MA, Finelli A, Kwast TV, Evans A, Sweet J, Laato M, Zlotta AR: Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. BJU Int 2012;110:804-811.
6.
Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y: Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007;51:137-149; discussion 149-151.
7.
Chapman DM, Pohar KS, Gong MC, Bahnson RR: Preoperative hydronephrosis as an indicator of survival after radical cystectomy. Urol Oncol 2009;27:491-495.
8.
Stimson CJ, Cookson MS, Barocas DA, Clark PE, Humphrey JE, Patel SG, Smith JA Jr, Chang SS: Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol 2010;183:1732-1737.
9.
Lin HY, Wang SZ, Chen JX, Chen LW, Xiao J: The prognostic value of hydronephrosis in bladder cancer treated by radical cystectomy. Urologia 2011;78:17-21.
10.
Green DA, Rink M, Hansen J, Cha EK, Robinson B, Tian Z, Chun FK, Tagawa S, Karakiewicz PI, Fisch M, Scherr DS, Shariat SF: Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. BJU Int 2013;111:404-411.
11.
Mitra AP, Skinner EC, Miranda G, Daneshmand S: A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer. BJU Int 2013;111:240-248.
12.
Canter D, Long C, Kutikov A, Plimack E, Saad I, Oblaczynski M, Zhu F, Viterbo R, Chen DY, Uzzo RG, Greenberg RE, Boorjian SA: Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int 2011;107:58-62.
13.
Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L: FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 2005;32:1412-1417.
14.
Gofrit ON, Mishani E, Orevi M, Klein M, Freedman N, Pode D, Shapiro A, Katz R, Libson E, Chisin R: Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. J Urol 2006;176:940-944; discussion 944.
15.
Anjos DA, Etchebehere EC, Ramos CD, Santos AO, Albertotti C, Camargo EE: 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med 2007;48:764-770.
16.
Jadvar H, Quan V, Henderson RW, Conti PS: [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol 2008;13:42-47.
17.
Kibel AS, Dehdashti F, Katz MD, Klim AP, Grubb RL, Humphrey PA, Siegel C, Cao D, Gao F, Siegel BA: Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 2009;27:4314-4320.
18.
Swinnen G, Maes A, Pottel H, Vanneste A, Billiet I, Lesage K, Werbrouck P: FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 2010;57:641-647.
19.
Apolo AB, Riches J, Schoder H, Akin O, Trout A, Milowsky MI, Bajorin DF: Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol 2010;28:3973-3978.
20.
Lodde M, Lacombe L, Friede J, Morin F, Saourine A, Fradet Y: Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int 2010;106:658-663.
21.
Golan S, Sopov V, Baniel J, Groshar D: Comparison of 11C-choline with 18F-FDG in positron emission tomography/computerized tomography for staging urothelial carcinoma: a prospective study. J Urol 2011;186:436-441.
22.
Jensen TK, Holt P, Gerke O, Riehmann M, Svolgaard B, Marcussen N, Bouchelouche K: Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology. Scand J Urol Nephrol 2011;45:122-128.
23.
Maurer T, Souvatzoglou M, Kubler H, Opercan K, Schmidt S, Herrmann K, Stollfuss J, Weirich G, Haller B, Gschwend JE, Schwaiger M, Krause BJ, Treiber U: Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol 2012;61:1031-1038.
24.
Orevi M, Klein M, Mishani E, Chisin R, Freedman N, Gofrit ON: 11C-acetate PET/CT in bladder urothelial carcinoma: intraindividual comparison with 11C-choline. Clin Nucl Med 2012;37:e67-e72.
25.
Schoder H, Ong SC, Reuter VE, Cai S, Burnazi E, Dalbagni G, Larson SM, Bochner BH: Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer. Mol Imaging Biol 2012;14:245-251.
26.
Vargas HA, Akin O, Schoder H, Olgac S, Dalbagni G, Hricak H, Bochner BH: Prospective evaluation of MRI, 11C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. Eur J Radiol 2012;81:4131-4137.
27.
Liedberg F, Mansson W: Lymph node metastasis in bladder cancer. Eur Urol 2006;49:13-21.
28.
Shariat SF, Ehdaie B, Rink M, Cha EK, Svatek RS, Chromecki TF, Fajkovic H, Novara G, David SG, Daneshmand S, Fradet Y, Lotan Y, Sagalowsky AI, Clozel T, Bastian PJ, Kassouf W, Fritsche HM, Burger M, Izawa JI, Tilki D, Abdollah F, Chun FK, Sonpavde G, Karakiewicz PI, Scherr DS, Gonen M: Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol 2012;61:237-242.
29.
Sobin LH, Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-1804.
30.
Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343-346.
32.
Liedberg F, Bendahl PO, Davidsson T, Gudjonsson S, Holmer M, Mansson W, Wallengren NO: Preoperative staging of locally advanced bladder cancer before radical cystectomy using 3 tesla magnetic resonance imaging with a standardized protocol. Scand J Urol 2013;47:108-112.
33.
Nakagawa T, Kanai Y, Nakanishi H, Komiyama M, Fujimoto H: Characteristics of lymph node metastases defining the outcome after radical cystectomy of urothelial bladder carcinoma. Jpn J Clin Oncol 2012;42:1066-1072.
34.
Simone G, Papalia R, Ferriero M, Guaglianone S, Naselli A, Collura D, Introini C, Puppo P, Muto G, Gallucci M: Development and external validation of lymph node density cut-off points in prospective series of radical cystectomy and pelvic lymph node dissection. Int J Urol 2012;19:1068-1074.
35.
Lee EK, Herr HW, Dickstein RJ, Kassouf W, Munsell MF, Grossman HB, Dinney CP, Kamat AM: Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy. BJU Int 2012;110:E590-E595.
36.
Bruins HM, Huang GJ, Cai J, Skinner DG, Stein JP, Penson DF: Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. J Urol 2009;182:2182-2187.
37.
Picchio M, Treiber U, Beer AJ, Metz S, Bossner P, van Randenborgh H, Paul R, Weirich G, Souvatzoglou M, Hartung R, Schwaiger M, Piert M: Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med 2006;47:938-944.
38.
Drzezga A, Souvatzoglou M, Eiber M, Beer AJ, Furst S, Martinez-Moller A, Nekolla SG, Ziegler S, Ganter C, Rummeny EJ, Schwaiger M: First clinical experience with integrated whole-body PET/MR: Comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 2012;53:845-855.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.